Orforglipron: Weight Management Efficacy & Tolerability
- more than 1 billion people worldwide are impacted by obesity, a condition defined by a Body Mass Index (BMI) of 30 or higher.
- Eli Lilly is developing orforglipron, a first-of-its-kind oral medication belonging to a class of drugs called glucagon-like-peptide-1 receptor agonists (GLP-1 RAs).
- GLP-1 ras work by mimicking the effects of the naturally occurring GLP-1 hormone, which plays a crucial role in regulating appetite and blood sugar.
A new Pill for Weight Loss? Orforglipron shows Promise in Clinical Trials
Table of Contents
Published August 22, 2025
The Growing Challenge of Obesity
more than 1 billion people worldwide are impacted by obesity, a condition defined by a Body Mass Index (BMI) of 30 or higher. This isn’t simply a cosmetic concern; obesity substantially elevates the risk of serious health complications, including heart disease, type 2 diabetes, high blood pressure, stroke, liver disease, and sleep apnea according to the Mayo clinic. Addressing this global health crisis requires innovative solutions.
Introducing Orforglipron: A Potential Game Changer
Eli Lilly is developing orforglipron, a first-of-its-kind oral medication belonging to a class of drugs called glucagon-like-peptide-1 receptor agonists (GLP-1 RAs). Unlike existing GLP-1 therapies which require injections, orforglipron is a small-molecule pill taken daily. This offers a potentially more convenient and accessible option for individuals struggling with weight management and related health issues.
GLP-1 ras work by mimicking the effects of the naturally occurring GLP-1 hormone, which plays a crucial role in regulating appetite and blood sugar. Specifically, orforglipron stimulates insulin release from the pancreas and slows down the rate at which food leaves the stomach, promoting feelings of fullness and reducing overall food intake.
The ATTAIN-1 Trial: Significant Results
The positive results stem from the Phase 3 ATTAIN-1 trial (NCT05869903), a rigorous 72-week, randomized, double-blind, placebo-controlled study involving 3,127 participants. The study focused on adults with obesity or who were overweight with at least one weight-related health condition - such as hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea – but did *not* have diabetes. Participants were assigned to receive either 6mg, 12mg, or 36mg of orforglipron, or a placebo.
The primary goal of the trial was to determine if orforglipron was more effective than a placebo in promoting weight loss. the results were compelling: participants receiving the highest dose (36mg) of orforglipron experienced an average weight loss of 27.3 pounds over the 72-week period. Furthermore, a substantial proportion of participants – 59.6% – lost nearly 10% of their body weight, and 39.6% achieved a weight loss of at least 15%.
beyond weight loss,the study also revealed positive effects on cardiovascular risk factors. All three doses of orforglipron led to reductions in non-HDL cholesterol, triglycerides, and systolic blood pressure.
| Orforglipron Dose | Average Weight Loss (lbs) | % of participants Losing ≥10% Body Weight | % of Participants Losing ≥15% Body Weight |
|---|---|---|---|
| 6 mg | Data not specified in source | Data not specified in source | Data not specified in source |
| 12 mg | Data not specified in source | Data not specified in source | data not specified in source |
| 36 mg | 27.3 | 59.6% | 39.6% |
| Placebo | Data not specified in source | Data not specified in source | Data not specified in source |
Safety and Side Effects
While generally well-tolerated,orforglipron was associated with some side effects,primarily gastrointestinal in nature. These included nausea, constipation, diarrhea, vomiting, and dyspepsia. A higher percentage of participants taking orforglipron experienced adverse event-related discontinuation compared to those receiving the placebo, with a 10.3% discontinuation rate in the 36mg group. However, overall discontinuation rates – including all reasons for leaving the study – were *lower* in the orforglipron groups compared to the placebo group.
What’s Next for Orforglipron?
“With orforglipron, we’re working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management while offering a convenient choice to injectable treatments,” said Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health in a news release issued August 7, 2025.
Lilly plans to submit orforglipron for regulatory review before the end of 2025, paving the way for a potential global launch to address the urgent need for effective obesity treatments.